商品情報にスキップ
1 2

Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story

通常価格 ¥1,078 JPY
通常価格 セール価格 ¥1,078 JPY
セール 売り切れ
税込み。
書籍サイズ
ページ数

In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had received approval several years prior. Moreover, Vectibix had also received Food and Drug Administration approval in 2006. During additional trials, Amgen has learned that the Vectibix is only effective with the 60% of the population that has a specific gene marker. Given this development, what should Amgen's strategy around Vectibix be both in Europe and the United States?

【書誌情報】

ページ数:8ページ

サイズ:A4

商品番号:HBSP-810066

発行日:2009/11/6

登録日:2010/4/7

1 3